Galapagos NV Stock price

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam 12:37:14 2024-03-28 pm EDT 5-day change 1st Jan Change
29.58 EUR -2.50% Intraday chart for Galapagos NV -3.80% -20.03%
Sales 2023 784M 845M Sales 2024 * 405M 437M Capitalization 1.95B 2.1B
Net income 2023 212M 229M Net income 2024 * -61M -65.82M EV / Sales 2023 3.11 x
Net cash position 2023 * 3.62B 3.9B Net cash position 2024 * 3.45B 3.72B EV / Sales 2024 * -3.7 x
P/E ratio 2023
11.5 x
P/E ratio 2024 *
-42.1 x
Employees 1,338
Yield 2023 *
-
Yield 2024 *
-
Free-Float 74.6%
More Fundamentals * Assessed data
Dynamic Chart
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41 MT
Galapagos NV Announces Board Changes CI
Galapagos to Seek Acquisitions CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024
Frontier Medicines Corporation announced that it has received $80.000001 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024 CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma MT
Frontier Medicines Corporation announced that it expects to receive $99.999997 million in funding CI
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV. CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S CI
Galapagos Partners with Thermo Fisher for Manufacturing in US MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network MT
Galapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer Drug DJ
More news
1 day-2.50%
1 week-4.33%
Current month-10.06%
1 month-13.13%
3 months-19.58%
6 months-9.60%
Current year-20.03%
More quotes
1 week
29.45
Extreme 29.45
30.73
1 month
29.45
Extreme 29.45
33.70
Current year
29.45
Extreme 29.45
39.00
1 year
29.45
Extreme 29.45
41.92
3 years
29.45
Extreme 29.45
69.82
5 years
29.45
Extreme 29.45
252.90
10 years
10.00
Extreme 10
252.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 22-03-31
Director of Finance/CFO 54 23-06-30
Investor Relations Contact - 20-10-31
Members of the board TitleAgeSince
Director/Board Member 66 22-04-25
Director/Board Member 65 23-09-18
Director/Board Member 61 19-10-21
More insiders
Date Price Change Volume
24-03-28 29.58 -2.50% 186,732
24-03-27 30.34 +0.33% 58,384
24-03-26 30.24 +0.67% 95,952
24-03-25 30.04 -1.41% 67,800
24-03-22 30.47 -0.91% 89,393

Real-time Euronext Amsterdam, March 28, 2024 at 12:37 pm EDT

More quotes
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
29.58 EUR
Average target price
39.43 EUR
Spread / Average Target
+33.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Galapagos NV - Euronext Amsterdam